Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK ‐ ERK and NF ‐κB pathways in a model of chronic myeloid leukemia-Reference-Cited by-同舟云学术

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK ‐ ERK and NF ‐κB pathways in a model of chronic myeloid leukemia

Published:2018-04-06 Issue:5 Volume:12 Page:630-647
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Chorzalska Anna¹,Ahsan Nagib²^ORCID,Rao R. Shyama Prasad³^ORCID,Roder Karim⁴,Yu Xiaoqing⁵,Morgan John⁶,Tepper Alexander¹,Hines Steven¹,Zhang Peng⁴,Treaba Diana O.⁷^ORCID,Zhao Ting C.⁸,Olszewski Adam J.⁹^ORCID,Reagan John L.⁹^ORCID,Liang Olin⁹^ORCID,Gruppuso Philip A.¹⁰^ORCID,Dubielecka Patrycja M.¹^ORCID

Affiliation:

1. Signal Transduction Lab Division of Hematology/Oncology Rhode Island Hospital Warren Alpert Medical School Brown University Providence RI USA

2. Division of Biology and Medicine COBRE CCRD Proteomics Core Facility Rhode Island Hospital Brown University Providence RI USA

3. Division of Biostatistics and Bioinformatics Yenepoya Research Center Yenepoya University Mangalore India

4. Cardiovascular Research Center Rhode Island Hospital Warren Alpert Medical School Brown University Providence RI USA

5. Department of Biostatistics Yale School of Public Health New Haven CT USA

6. Flow Cytometry and Cell Sorting Core Facility Roger Williams Medical Center Providence RI USA

7. Department of Pathology and Laboratory Medicine Rhode Island Hospital Warren Alpert Medical School Brown University Providence RI USA

8. Cardiovascular Lab Department of Surgery Roger Williams Medical Center Boston University School of Medicine Providence RI USA

9. Division of Hematology/Oncology Rhode Island Hospital Warren Alpert Medical School Brown University Providence RI USA

10. Department of Pediatrics Rhode Island Hospital Brown University Providence RI USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12186

Reference77 articles.

1. Highly reproducible improved label-free quantitative analysis of cellular phosphoproteome by optimization of LC-MS/MS gradient and analytical column construction

2. A probability-based approach for high-throughput protein phosphorylation analysis and site localization

3. Functions of NF-κB1 and NF-κB2 in immune cell biology

4. Uncoupling of Hepatic, Epidermal Growth Factor-mediated Mitogen-activated Protein Kinase Activation in the Fetal Rat

5. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel targeted therapies in chronic myeloid leukemia;Pharmaceutical Science Advances;2024-09

2. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia;Cell Death & Disease;2024-08-23

3. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia;2024-02-20

4. The importance of personalized medicine in chronic myeloid leukemia management: a narrative review;Egyptian Journal of Medical Human Genetics;2023-04-06

5. Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells;Cell Proliferation;2023-02-27